Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Lilly Blood Thinner Prasugrel Earns EU Approval

By Pharmaceutical Processing | February 23, 2009

By TOM MURPHY AP Business Writer INDIANAPOLIS (AP) — European Union regulators have approved the blood thinner prasugrel, drugmaker Eli Lilly & Co. announced Monday morning. The European Commission granted marketing authorization for prasugrel, which will be sold in Europe under the brand name Efient. Lilly spokeswoman Carole Copeland said the drug will be launched “in the coming weeks,” with a separate rollout in each country. Indianapolis-based Lilly developed prasugrel with Japanese drugmaker Daiichi Sankyo Co., and the two companies will share revenue. The drug is designed to prevent dangerous blood clots from forming in patients with acute heart problems, like heart attacks, who have had stents implanted in their arteries .Prasugrel will compete with the blockbuster blood thinner Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis. Plavix had U.S. sales of $4.9 billion last year and was the world’s second best-selling prescription medicine. Some analysts predict that prasugrel, which will be sold as Effient if approved in the United States, could surpass $1 billion in annual sales within a few years. Lilly and Daiichi Sankyo are still waiting for approval from U.S. regulators. But prasugrel won a strong endorsement earlier this month, when a nine-member Food and Drug Administration cardiology panel voted unanimously in favor of the drug’s approval. The FDA still must decide whether to approve it. The agency has twice delayed making a decision on the drug and is not required to follow the advice of the panel, though it usually does. Copeland said Lilly officials are still talking with U.S. regulators, but she had no time frame for that approval. “We’re still confident in that submission and working diligently with them as they continue their review,” she said.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE